Search hospitals > Kentucky > Louisville
Norton Cancer Institute
Claim this profileLouisville, Kentucky 40202
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Pancreatic Cancer
Conducts research for Lymphoma
Conducts research for Non-Small Cell Lung Cancer
220 reported clinical trials
13 medical researchers
Summary
Norton Cancer Institute is a medical facility located in Louisville, Kentucky. This center is recognized for care of Cancer, Lung Cancer, Pancreatic Cancer, Lymphoma, Non-Small Cell Lung Cancer and other specialties. Norton Cancer Institute is involved with conducting 220 clinical trials across 200 conditions. There are 13 research doctors associated with this hospital, such as John Hamm, MD, Don Stevens, MD, Jaspreet Grewal, MD, and Joseph Maly.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
2Lung Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
Top PIs
John Hamm, MDNorton Cancer Institute6 years of reported clinical research
Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
27 reported clinical trials
47 drugs studied
Don Stevens, MDNorton Cancer Institute3 years of reported clinical research
Studies Non-Hodgkin's Lymphoma
Studies B-Cell Lymphoma
26 reported clinical trials
46 drugs studied
Jaspreet Grewal, MDNorton Cancer Institute4 years of reported clinical research
Studies Head and Neck Cancers
Studies Squamous Cell Carcinoma
10 reported clinical trials
16 drugs studied
Joseph MalyNorton Cancer Institute4 years of reported clinical research
Studies Lymphoma
Studies Acute Myelogenous Leukemia
9 reported clinical trials
19 drugs studied
Clinical Trials running at Norton Cancer Institute
Non-Hodgkin's Lymphoma
Lung Cancer
Multiple Myeloma
Cancer
Ovarian Cancer
Breast Cancer
Pancreatic Cancer
Non-Small Cell Lung Cancer
B-Cell Lymphoma
Colorectal Cancer
RNK05047
for Cancer
This trial tests RNK05047, a new drug, on patients with advanced solid tumors, including DLBCL. The drug is given regularly through an IV to find the safest and most effective dose.
Recruiting1 award Phase 1 & 2
REGN5837 + Odronextamab
for Aggressive B-Cell Lymphoma
The study is researching an experimental drug called REGN5837 in combination with another experimental drug, odronextamab (called "study drugs"). The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose for phase 2. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (that could make the drugs less effective or could lead to side effects) * To find out how well the study drugs work against relapsed or refractory aggressive B-cell non-Hodgkin lymphomas (B-NHLs)
Recruiting1 award Phase 1
Cema-cel
for B-Cell Lymphoma
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. In this study, participants with MRD are randomized 1:1 to treatment with cema-cel or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide. Prior to August 2025, participants may also have received an anti-CD52 monoclonal antibody, ALLO-647, as part of their lymphodepletion regimen.
Recruiting1 award Phase 25 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Norton Cancer Institute?
Norton Cancer Institute is a medical facility located in Louisville, Kentucky. This center is recognized for care of Cancer, Lung Cancer, Pancreatic Cancer, Lymphoma, Non-Small Cell Lung Cancer and other specialties. Norton Cancer Institute is involved with conducting 220 clinical trials across 200 conditions. There are 13 research doctors associated with this hospital, such as John Hamm, MD, Don Stevens, MD, Jaspreet Grewal, MD, and Joseph Maly.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.